Logo image of IART

INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IART - US4579852082 - Common Stock

13.15 USD
-0.43 (-3.17%)
Last: 1/12/2026, 8:00:02 PM
13 USD
-0.15 (-1.14%)
After Hours: 1/12/2026, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, IART scores 4 out of 10 in our fundamental rating. IART was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

IART had positive earnings in the past year.
In the past year IART had a positive cash flow from operations.
IART had positive earnings in 4 of the past 5 years.
In the past 5 years IART always reported a positive cash flow from operatings.
IART Yearly Net Income VS EBIT VS OCF VS FCFIART Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

1.2 Ratios

IART has a Return On Assets (-13.58%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -47.74%, IART is in line with its industry, outperforming 51.89% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.27%, IART is in the better half of the industry, outperforming 74.59% of the companies in the same industry.
IART had an Average Return On Invested Capital over the past 3 years of 6.10%. This is below the industry average of 8.84%.
Industry RankSector Rank
ROA -13.58%
ROE -47.74%
ROIC 4.27%
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
IART Yearly ROA, ROE, ROICIART Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8 10

1.3 Margins

IART's Operating Margin of 10.22% is fine compared to the rest of the industry. IART outperforms 78.92% of its industry peers.
In the last couple of years the Operating Margin of IART has declined.
IART has a Gross Margin of 57.21%. This is comparable to the rest of the industry: IART outperforms 56.76% of its industry peers.
In the last couple of years the Gross Margin of IART has declined.
Industry RankSector Rank
OM 10.22%
PM (TTM) N/A
GM 57.21%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
IART Yearly Profit, Operating, Gross MarginsIART Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IART is destroying value.
Compared to 1 year ago, IART has less shares outstanding
Compared to 5 years ago, IART has less shares outstanding
IART has a worse debt/assets ratio than last year.
IART Yearly Shares OutstandingIART Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IART Yearly Total Debt VS Total AssetsIART Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 1.27, we must say that IART is in the distress zone and has some risk of bankruptcy.
IART has a Altman-Z score (1.27) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.73 is on the high side and indicates that IART has dependencies on debt financing.
The Debt to Equity ratio of IART (1.73) is worse than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Altman-Z 1.27
ROIC/WACC0.53
WACC8.05%
IART Yearly LT Debt VS Equity VS FCFIART Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.3 Liquidity

IART has a Current Ratio of 3.14. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
IART has a Current ratio of 3.14. This is comparable to the rest of the industry: IART outperforms 58.38% of its industry peers.
IART has a Quick Ratio of 1.80. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
IART has a Quick ratio (1.80) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 1.8
IART Yearly Current Assets VS Current LiabilitesIART Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

4

3. Growth

3.1 Past

IART shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
The Earnings Per Share has been decreasing by -1.35% on average over the past years.
The Revenue has been growing slightly by 4.99% in the past year.
The Revenue has been growing slightly by 1.20% on average over the past years.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%

3.2 Future

IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.68% yearly.
IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.39% yearly.
EPS Next Y-12.33%
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
EPS Next 5Y2.68%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IART Yearly Revenue VS EstimatesIART Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
IART Yearly EPS VS EstimatesIART Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 5.55, which indicates a rather cheap valuation of IART.
IART's Price/Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 98.38% of the companies in the same industry.
IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.25.
IART is valuated cheaply with a Price/Forward Earnings ratio of 5.48.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 99.46% of the companies listed in the same industry.
IART is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.98, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.55
Fwd PE 5.48
IART Price Earnings VS Forward Price EarningsIART Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

IART's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IART is cheaper than 95.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.11
IART Per share dataIART EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.22%
EPS Next 3Y1.53%

0

5. Dividend

5.1 Amount

IART does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (1/12/2026, 8:00:02 PM)

After market: 13 -0.15 (-1.14%)

13.15

-0.43 (-3.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-23 2026-02-23/amc
Inst Owners95.82%
Inst Owner Change0.6%
Ins Owners3.07%
Ins Owner Change0.13%
Market Cap1.02B
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target15.81 (20.23%)
Short Float %10.29%
Short Ratio6.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)0%
PT rev (3m)-5.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-5.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.35%
Valuation
Industry RankSector Rank
PE 5.55
Fwd PE 5.48
P/S 0.62
P/FCF N/A
P/OCF 11.47
P/B 0.99
P/tB N/A
EV/EBITDA 8.11
EPS(TTM)2.37
EY18.02%
EPS(NY)2.4
Fwd EY18.23%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY8.72%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
Industry RankSector Rank
ROA -13.58%
ROE -47.74%
ROCE 5.11%
ROIC 4.27%
ROICexc 4.65%
ROICexgc 11.32%
OM 10.22%
PM (TTM) N/A
GM 57.21%
FCFM N/A
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Debt/EBITDA 5.62
Cap/Depr 68.73%
Cap/Sales 6.32%
Interest Coverage 250
Cash Conversion 28.01%
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 1.8
Altman-Z 1.27
F-Score5
WACC8.05%
ROIC/WACC0.53
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.33%
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.61%
EBIT Next 3Y9.61%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%

INTEGRA LIFESCIENCES HOLDING / IART FAQ

Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?

ChartMill assigns a fundamental rating of 4 / 10 to IART.


What is the valuation status for IART stock?

ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.


What is the profitability of IART stock?

INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.


What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?

The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.